Resistance to targeted therapies: delving into FLT3 and IDH
Sai Prasad Desikan, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Marina Konopleva, Farhad Ravandi
Abstract
Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.
Topics & Concepts
MedicineBiologyInternal medicineOncologyBioinformaticsCancer researchAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia Treatments